The U.S. Food and Drug Administration (FDA) has cleared new indications for a brachytherapy device from Xoft of Sunnyvale, CA.
The company's Axxent electronic brachytherapy system is designed to be used in minimally shielded environments and to deliver localized, nonradioactive, isotope-free radiation treatment. The product was previously cleared for accelerated treatment of early-stage breast cancer, but is now available for treatment of other cancers in which radiation therapy is indicated, the company reported.
Related Reading
Xoft reports new CPT code, July 26, 2007
Xoft reaches milestone, April 25, 2007
FDA clears Xoft brachytherapy unit, January 5, 2006
Varian, Xoft sign distribution deal, October 13, 2005
Copyright © 2007 AuntMinnie.com
